Numis Securities Reiterates Buy Rating for BTG (BTG)
BTG has been the subject of several other research reports. JPMorgan Chase & Co. reaffirmed a neutral rating on shares of BTG in a research report on Monday, January 15th. Peel Hunt reaffirmed a hold rating and set a GBX 700 ($9.83) price target on shares of BTG in a research report on Thursday. Finally, Deutsche Bank reaffirmed a buy rating and set a GBX 775 ($10.88) price target on shares of BTG in a research report on Friday, October 13th. Two analysts have rated the stock with a hold rating and six have given a buy rating to the company. BTG presently has an average rating of Buy and a consensus price target of GBX 774.13 ($10.87).
BTG (BTG) opened at GBX 717 ($10.07) on Thursday. The firm has a market cap of $2,770.00 and a P/E ratio of 3,773.68. BTG has a 52-week low of GBX 531 ($7.46) and a 52-week high of GBX 784 ($11.01).
BTG Company Profile
BTG plc is engaged in the business of healthcare, focusing on Interventional Medicine therapies for liver cancer, emphysema and vascular disorders, specialty pharmaceuticals for acute care uses, and a licensing business. The Company operates through three segments: Interventional Medicine, Specialty Pharmaceuticals and Licensing.
Receive News & Ratings for BTG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BTG and related companies with MarketBeat.com's FREE daily email newsletter.